Development of standardized immunoassays and virus panels for HCV vaccine research

开发用于 HCV 疫苗研究的标准化免疫测定和病毒组

• 批准号: 10456321
• 负责人: Justin Richard Bailey
• 金额: $ 54.2万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-23 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10456321
• 关键词: Adopted; Antibodies; Antibody Response; Antibody titer measurement; Antigens; Biological Assay; Cells; Data; Development; Generations; Genetic Polymorphism; Genetic Variation; Genotype; Glycoproteins; Hepatitis C Antibodies; Hepatitis C Vaccine; Hepatitis C virus; Immune; Immune Plasma; Immunoassay; Individual; Infection; Laboratories; Laboratory Research; Measurement; Measures; Phenotype; Play; Preparation; Reagent; Reproducibility; Role; Standardization; Vaccination; Vaccine Research; Vaccines; Validation; Variant; Viral Antigens; Virus; adaptive immune response; base; env Gene Products; human subject; improved; neutralizing antibody; neutralizing monoclonal antibodies; novel; pandemic disease; vaccine candidate; vaccine development; virus envelope

Project Summary Given the ongoing hepatitis C virus (HCV) pandemic, HCV vaccine development is an urgent priority. Despite the extraordinary genetic diversity of the virus, some antibodies are broadly neutralizing, meaning that these antibodies are able to block infection by genetically diverse HCV isolates. Stimulation of broadly neutralizing antibodies is likely to be a major component of a protective HCV vaccine, so accurate and standardized measurement of antibody titers and neutralization breadth is key to accelerating HCV vaccine development. However, there is currently no standard assay or panel of HCV envelope proteins or viruses used to measure antibody titers or neutralization. We propose here to develop pure HCV antigens and a standardized immunoassay for quantification of anti-HCV antibody responses to vaccination, and to develop a standardized HCV neutralization panel with genetically and phenotypically diverse viruses for quantification of neutralizing antibody responses to vaccination. These reference panels could be adopted as a standard for measurement of antibody titers and neutralizing breadth, which would allow meaningful comparisons of results obtained in different laboratories, and more rapid advancement of HCV vaccine development. Development of an HCV vaccine is an urgent priority. Accurate and standardized measurement of the titers, neutralizing potency and breadth of antibodies using diverse HCV isolates is key to evaluating HCV vaccine candidates and comparing results obtained in different laboratories. By generation of pure HCV antigens, a standardized immunoassay, and a standardized neutralization panel, we will facilitate accurate, reproducible measurements of antibody responses, and accelerate HCV vaccine development.

项目总结